Etymology
* The word diachysis derives from the Greek word, διάχυσησ, which means "Liver failure
In hyperacute and acute liver failure the clinical picture develops rapidly with progressive encephalopathy and multiorgan dysfunction such asBioartificial liver devices
Bioartificial liver devices are experimental extracorporeal devices that use living cell lines to provide detoxification and synthesis support to the failing liver. Bio-artificial liver (BAL) Hepatassist 2000 uses porcine hepatocytes whereas ELAD system employs hepatocytes derived from human hepatoblastoma C3A cell lines. Both techniques can produce, in fulminant hepatic failure (FHF), an improvement of hepatic encephalopathy grade and biochemical parameters. Nevertheless, they are therapies with high complexity that require a complex logistic approach for implementation; a very high cost and possible inducement of important side effects such as immunological issues (porcine endogenous retrovirus transmission), infectious complications and tumor transmigration have been documented. Other biological hepatic systems are Bioartificial Liver Support (BLSS) and Radial Flow Bioreactor (RFB). Detoxification capacity of these systems is poor and therefore they must be used combined with other systems to mitigate this deficiency. Today its use is limited to centers with high experience in their application. A bioartificial liver device (BAL) is an artificialHistory
Early history
The first bioartificial liver device was developed in 1993 by Dr. Achilles A. Demetriou at Cedars-Sinai Medical Center. The bioartificial liver helped an 18-year-old southern California woman survive without her own liver for 14 hours until she received a human liver using a 20-inch-long, 4-inch-wide plastic cylinder filled with cellulose fibers and pig liver cells. Blood was routed outside the patient's body and through the artificial liver before being returned to the body. Dr Kenneth Matsumara's work on the BAL led it to be named an invention of the year by ''Time'' magazine in 2001. Liver cells obtained from an animal were used instead of developing a piece of equipment for each function of theDevelopment
Advancements inUse
The purpose of BAL-type devices, currently, is not to permanently replace liver functions, but to serve as a supportive device, either allowing the liver to regenerate properly upon acute liver failure, or to bridge the individual's liver functions until a transplant is possible.Function
BALs are essentiallyHollow fibre systems
One type of BAL is similar toCryogel-Based Systems
Currently, hollow-fibre bioreactors are the most commonly accepted design for clinical use due to their capillary-network allowing for easy perfusion of plasma across cell populations. However, these structures have their limitations, with convectional transport issues, nutritional gradients, non-uniform seeding, inefficient immobilisation of cells, and reduced hepatocyte growth restricting their effectiveness in BAL designs. Researchers are now investigating the use of cryogels to replace hollow-fibres as the cell carrier components in BAL systems. Cryogels are super-macroporous three-dimensional polymers prepared at sub-zero temperatures, by the freezing of a solution of cryogel precursors and solvent. The pores develop during this freezing process – as the cryogel solution cools, the solvent begins to form crystals. This causes the concentration of the cryogel precursors in the solution to increase, initiating the cryogelation process and forming the polymer walls. As the cryogel warms, the solvent crystals thaw, leaving cavities that form the pores. Cryogel pores range in size from 10-100 µm in size, forming an interconnected network that mimics a capillary system with a very large surface area to volume ratio, supporting large numbers of immobilised cells. Convection mediated transport is also supported by cryogels, enabling even distribution of nutrients and metabolite elimination, overcoming some of the shortcomings of hollow-fibre systems. Most importantly, cryogel scaffolds demonstrate good mechanical strength and biocompatibility without triggering an immune response, improving their potential for long-term inclusion in BAL devices or ''in-vitro'' use. Another advantage of cryogels is their flexibility for use in a variety of tasks, including separation and purification of substances, along with acting as extracellular matrix for cell growth and proliferation. Immobilisation of specific ligands onto cryogels enables adsorption of specific substances, supporting their use as treatment options for toxins, for separation of haemoglobin from blood, and as a localised and sustained method for drug delivery. Jain ''et al.'' investigated poly(AN-''co''-NVP) and poly(NiPAAm)-chitosan cryogels as hepatocyte carriers in a BAL system. These cryogel polymers were chosen as they maintain a good balance of hydrophilicity/hydrophobicity to promote hepatocyte binding. Chitosan was added to cryogels as it promotes spheroid formation in hepatocytes, an indicator of healthy growth. The researchers were able to demonstrate biocompatibility with human HepG2 cells after high-density growth for 7 days, and with surrounding tissue after implantation into mice. They also evaluated ureagenesis and drug detoxification by hepatocytes in the scaffold, finding that over time the hepatocytes were able to process ammonia into urea, and that CYP450 activity in the cells after 96 hours culturing was equal to that of freshly isolated hepatocytes. The researchers then seeded HepG2 cells onto cryogels and incubated for 48 hours, before incorporating the cryogels into a BAL bioreactor. They circulated plasma isolated from alcoholic ACLF patients for 3 hours through the bioreactor and ran control experiments with cryogels incubated in media only. After the experiment, they found that the cell-seeded bioreactors had reduced the levels of bilirubin and ammonia in the plasma (by 58.9 ± 6.7% and 61.2 ± 7%, respectively) and increased the level of albumin by 31.1 ± 28% compared to the control group. This demonstrated that the HepG2 cells in the bioreactor were able to carry out detoxifying and synthetic functions of normal liver cells. However, after 3 hours of plasma circulation, hepatocyte function deteriorated rapidly. This was likely due to the toxic effect of ACLF plasma on hepatocytes, or nutrient and oxygen depletion. The study clearly demonstrated the ability of HepG2 seeded cryogels to detoxify plasma and support liver function, however further research is needed into what caused the reduction in function after 3 hours. Damania ''et al.'' took this system a step further, utilising HepG2 seeded poly(NiPAAm)-chitosan cryogels in a bioreactor, along with an activated charcoal cloth used as a filter. As seen with the artificial BAL devices, activated charcoal is useful in the filtration of liver toxins, including ammonia and bilirubin. The researchers then incorporated the bioreactor into a rat model, connecting rats with induced liver failure to the system and passing their blood across a plasma-separation membrane, with the plasma running through the seeded cryogel and charcoal filter. They compared results against rats with induced liver failure who were not connected to a bioreactor. Measuring levels of ammonia, urea, bilirubin, albumin, and AST over a 3-hour time period, they found a reduction in bilirubin, AST, and urea levels and an increase in albumin levels, suggesting the bioreactor is functioning in its removal of toxins and synthesis of new proteins. In addition, they ran the same experiment using an acellular bioreactor, and found that bilirubin and AST decreased over time, but to a lesser degree than the seeded bioreactor, showing that the detoxification results of the seeded reactor were due to a combination of both the HepG2 cells, and the activated charcoal cloth. However, in the cell-seeded reactor there was an increase in the levels of ammonia, which the researchers stated could be attributed to these toxins having a detrimental effect on the cells over time, reducing their function.Clinical Studies
There have been numerous clinical studies involving hollow-fibre bioreactors. Overall, they show promise but do not provide statistically significant evidence supporting their effectiveness. This is generally due to inherent design limitations, causing convectional transport issues, nutritional gradients, non-uniform seeding, inefficient immobilisation of cells, and reduced hepatocyte growth. As of writing, no cryogel-based devices have entered clinical trials. However, laboratory results have been promising, and hopefully trials will begin soon.HepatAssist
The HepatAssist, developed at the Cedars-Sinai Medical Center, is a BAL device containing porcine hepatocytes within a hollow-fibre bioreactor. These semi-permeable fibres act as capillaries, allowing the perfusion of plasma through the device, and across the hepatocytes surrounding the fibres. The system incorporates a charcoal column to act as a filter, removing additional toxins from the plasma. Demetriou ''et al.'' carried out a large, randomised, multicentre, controlled trial on the safety and efficacy of the HepatAssist device. 171 patients with ALF stemming from viral hepatitis, paracetamol overdose or other drug complications, primary non-function (PNF), or of indeterminate aetiology, were involved in the study and were randomly assigned to either the experimental or control groups. Both groups were well balanced in terms of age, gender, race, and aetiology. The study found that at the primary end-point 30-day post admission mark, there was an increased survival rate in BAL patients over control patients (71% vs 62%), but the difference was not significant. However, when patients with PNF are excluded from the results there is a 44% reduction in mortality for BAL treated patients, a statistically significant advantage. The investigators noted that exclusion of PNF patients is justifiable due to early retransplantation and lack of intercranial hypertension, so HepatAssist would give little benefit to this group. For the secondary end-point of time-to-death, in patients with ALF of known aetiology there was a significant difference between BAL and control groups, with BAL patients surviving for longer. There was no significant difference for patients of unknown aetiology, however. The conclusions of the study suggest that such a device has potentially significant importance when used as a treatment measure. While the overall findings were not statistically significant, when the aetiology of the patients was taken into account the BAL group gained a statistically significant reduction in mortality over the control group. This suggests that while the device may not be applicable to patients as an overall treatment for liver dysfunction, it can provide an advantage when the heterogeneity of patients is considered and is used with patients of specific aetiology.Extracorporeal Liver Assist Device
The Extracorporeal Liver Assist Device (ELAD) is a human-cell based treatment system. A catheter removes blood from the patient, and an ultrafiltrate generator separates the plasma from the rest of the blood. This plasma is then run through a separate circuit containing cartridges filled with C3A cells, before being returned to the main circuit and re-entering the patient. C3A cells were chosen for this device due to their possession of anti-inflammatory proteins, such as IL-1 receptor antagonist, along with anti-apoptotic and anti-oxidative mechanisms that could aid in the reduction of further liver injury from the patients’ diseased state. Thompson ''et al.'' performed a large open-label trial, measuring the effectiveness of ELAD on patients with severe alcoholic hepatitis resulting in ACLF. Their study involved patients screened at 40 sites across the US, UK, and Australia, and enrolled a total of 203 patients. Patients were then randomised into either ELAD (n=96) or standard medical care (n=107) groups, with even distribution for patients in terms of sex, MELD score, and bilirubin levels. Of the 96 patients in the ELAD group, 45 completed the full 120 hours of treatment – the rest were unable to complete the full regimen due to a variety of reasons, including withdrawal of consent or severe adverse events, though 37 completed >72 hours of treatment, with results showing minimal difference in mortality between those receiving either >72 hours or the full 120 hours of treatment. The study was unable to complete its goal, finding no statistically significant improvement in mortality rates for patients that received ELAD treatment over those receiving standard care at 28 and 91 days (76.0% versus 80.4% and 59.4% versus 61.7%, respectively). Biomarker measurements showed a significantly reduced level of bilirubin and alkaline phosphatase in ELAD patients, though neither improvement translated into increased survivability rates. Outcomes for patients with MELD score <28 showed trends towards improved survival on ELAD, whereas those with MELD >28 had decreased survivability on ELAD. These patients presented with raised creatinine from kidney failure, suggesting a reason why ELAD decreased survival chance over standard care. Unlike artificial ELS devices and HepatAssist, ELAD does not incorporate any filtration devices, such as charcoal columns and exchange resins. Therefore, it cannot replace the filtration capability of the kidneys and cannot compensate for multi-organ failure from more severe presentations of ACLF, resulting in increased mortality rates. While the results of the study cannot provide conclusive evidence to suggest that a BAL device like ELAD improves the outcome of severe ACLF, it does suggest that it can aid the survival of patients with a less severe form of the disease. In those patients with a MELD <28, beneficial effects were seen 2–3 weeks post treatment, suggesting that while C3A incorporating BAL devices are unable to provide short-term aid like artificial albumin filtration devices, they instead provide more long-term aid in recovery of the patient’s liver. A randomized, phase 3 trial of the ELAD device in patients with severe alcoholic hepatitis failed to show benefit on overall survival and development was discontinued.Liver dialysis
Artificial liver support systems are aimed to temporally replace native liver detoxification functions and they usePrognosis/survival
While the technique is in its infancy, the prognosis of patients with liver failure remains guarded. Liver dialysis, currently, is only considered to be a bridge to transplantation or liver regeneration (in the case of acute liver failure) and, unlikeDevices
Artificial detoxification devices currently under clinical evaluation include the Single Pass Albumin Dialysis (SPAD), Molecular Adsorbent Recirculating System (MARS)®, Prometheus system, and Dialive.Single Pass Albumin Dialysis (SPAD)
Single pass albumin dialysis (SPAD) is a simple method ofMolecular adsorbents recirculation system
The Molecular Adsorbents Recirculation System (MARS) is the best known extracorporal liver dialysis system and has existed for approximately fifteen years. It consists of two separate dialysis circuits. The first circuit consists of human serum albumin, is in contact with the patient's blood through a semipermeable membrane and has two filters to clean the albumin after it has absorbed toxins from the patient's blood. The second circuit consists of a hemodialysis machine and is used to clean the albumin in the first circuit, before it is recirculated to the semipermeable membrane in contact with the patient's blood.Comparing SPAD, MARS and CVVHDF
SPAD, MARS and continuous veno-venous haemodiafiltration (CVVHDF) were comparedPrometheus
The Prometheus system ( Fresenius Medical Care,Dialive
Dialive (Yaqrit Limited, London, UK) incorporates albumin removal and replacement and, endotoxin removal. It is at "The MARS System
MARS was developed by a group of researchers at the University of Rostock (Germany), in 1993 and later commercialized for its clinical use in 1999. The system is able to replace the detoxification function of the liver while minimizing the inconvenience and drawbacks of previously used devices. ''In vivo'' preliminary investigations indicated the ability of the system to effectively remove bilirubin, biliary salts, free fatty acids and tryptophan while important physiological proteins such as albumin, alpha-1-glicoproteine, alpha 1 antitrypsin, alpha-2-macroglobulin, transferrin, globulin tyrosine, and hormonal systems are unaffected. Also, MARS therapy in conjunction with CRRT/HDF can help clear cytokines acting as inflammatory and immunological mediators in hepatocellular damage, and therefore can create the right environment to favour hepatocellular regeneration and recovery of native liver function.MARS System Components
MARS is an extracorporeal hemodialysis system composed of three different circuits: blood, albumin and low-flux dialysis. The blood circuit uses a double lumen catheter and a conventional hemodialysis device to pump the patient's blood into the MARS FLUX, a biocompatible polysulfone high-flux dialyser. With a membrane surface area of 2.1 m2, 100 nm of thickness and a cut-off of 50 KDa, the MARSFLUX is essential to retaining the albumin in the dialysate. Blood is dialysed against a human serum albumin (HSA) dialysate solution that allows blood detoxification of both water-soluble and protein-bound toxins, by means of the presence of albumin in the dialysate (albumin dialysis). The albumin dialysate is then regenerated in a close loop in the MARS circuit by passing through the fibres of the low-flux diaFLUX filter, to clear water-soluble toxins and provide electrolyte/acid-base balance, by a standard dialysis fluid. Next, the albumin dialysate passes through two different adsorption columns; protein-bound substances are removed by the diaMARS AC250, containing activated charcoal and anionic substances are removed by the diaMARS IE250, filled with cholestyramine, an anion-exchange resin. The albumin solution is then ready to initiate another detoxifying cycle of the patient's blood that can be sustained until both adsorption columns are saturated, eliminating the need to continuously infuse albumin into the system during treatment (Fig. 1).Results published in the literature with the MARS system
A systematic review of the literature from 1999 to June 2011 was performed in the following databases: # Specialized in systematic reviews: Cochrane Library Plus and NHS Centre database for Reviews and Dissemination (HTA, DARE and NHSEED). # General databases: Medline, Pubmed and Embase. # On-going clinical trials and research project databases: Clinical Trials Registry (National Institutes of Health, EE.UU.) and Health Services Research Projects in Progress. # General web searching engines: Scholar Google.Effects of MARS treatment on Hepatic Encephalopathy (HE)
Hepatic encephalopathy (HE) represents one of the more serious extrahepatic complications associated with liver dysfunction. Neuro-psychiatric manifestations of HE affect consciousness and behaviour. Evidence suggests that HE develops as some neurotoxins and neuro active substances, produced after hepatocellular breakdown, accumulates in the brain as a consequence of a portosystemic shunt and the limited detoxification capability of the liver. Substances involved are ammonia, manganese, aromatic aminoacids, mercaptans, phenols, medium chain fatty acids, bilirubin, endogenous benzodiazepines, etc.Effects of MARS Treatment on Unstable Hemodynamics
Hemodynamic instability is often associated with acute liver insufficiency, as a consequence of endogenous accumulation of vasoactive agents in the blood. This is characterized by a systemic vasodilatation, a decrease of systemic vascular resistance, arterial hypotension, and an increase of cardiac output that gives rise to a hyperdynamic circulation.Effects of MARS Treatment on Renal Function
Hepatorenal syndrome is one of the more serious complications in patients with an acute decompensation of cirrhosis and increased portal hypertension. It is characterized by hemodynamic changes in splanchnic, systemic and renal circulation. Splanchnic vasodilatation triggers the production of endogenous vasoactive substances that produce renal vasoconstriction and low glomerular filtration rate, leading to oliguria with a concomitant reduction in creatinine clearance. Renal insufficiency is always progressive with a very poor prognosis, with survival at 1 and 2 months of 20 and 10% respectively. Pierre Versin is one of the pioneers in the study of hepatorenal syndrome in patients with liver impairment. Great efforts have been made trying to improve the prognosis of this type of patient; however, few have solved the problem. Orthotopic liver transplantation is the only treatment that has shown to improve acute and chronic complications derived from severe liver insufficiency. Today it is possible to combine albumin dialysis with continuous veno-venous hemodialfiltration, which provides a greater expectation for these patients by optimization of their clinical status. MARS treatment lowers serum urea and creatinine levels improving their clearance, and even favors resolution of hepatorenal syndrome. Results are confirmed in a randomized controlled trial published by Mitzner ''et al.''. in which 13 patients diagnosed with hepatorenal syndrome type I were treated with MARS therapy. Mean survival was 25,2±34,6 days in the MARS group compared to 4,6±1,8 days observed in the controls in whom hemodiafiltration and standard care (SMT) was applied. This resulted in a statistically significance difference in survival at 7 and 30 days (p<0.05). Authors concluded that MARS therapy, applied to liver failure patients (Child-Pugh C and UNOS 2A scores) who develop hepatorenal syndrome type I, prolonged survival compared to patients treated with SMT. Although mechanisms explaining previous findings are not yet fully understood, it has been reported that there was a decrease in plasma rennin concentrations in patients diagnosed with acute on chronic liver failure with renal impairment that were treated with MARS. Likewise, other studies have suggested some efficacy for MARS in the treatment of hepatorenal syndrome.Effects of MARS Treatment on Biochemical Parameters
Total bilirubin was the only parameter analyzed in all trials that was always reduced in the groups of patients treated with MARS; Banayosy ''et al.''. measured bilirubin levels 14 days after since MARS therapy was terminated and observed a consistent, significant decrease not only for bilirubin but also for creatinine and urea (Table 6).Effects of MARS Treatment on Pruritus
Pruritus is one of the most common clinical manifestations in cholestasis liver diseases and one of the most distressing symptoms in patients with chronic liver disease caused by viral hepatitis C. Many hypothesis have been formulated to explain physio pathogenesis of such manifestation, including incremental plasma concentration of biliary acids, abnormalities in the bile ducts, increased central neurotransmitters coupling opioid receptors, etc..... Despite the number of historical drugs used, individually or combined (exchange resins, hydrophilic biliary acids, antihistamines, antibiotics, anticonvulsants, opioid antagonists), there are reported cases of intractable or refractory pruritus with a dramatic reduction in patients’ quality of life (i.e. sleep disorders, depression, suicide attempts...). Intractable pruritus can be an indication for liver transplantation. The MARS indication for intractable pruritus is therapeutically an option that has shown to be beneficial for patients in desperate cases, although at high cost. In several studies, it was confirmed that after MARS treatments, patients remain free from pruritus for a period of time ranging from 6 to 9 months. Nevertheless, some authors have concluded that besides the good results found in the literature, application of MARS therapy in refractory pruritus requires larger evidence.Effects of MARS Treatment on Drugs and Poisons clearance
Pharmacokinetics and pharmacodynamics for a majority of drugs can be significantly be modified with liver failure, affecting the therapeutic approach and potential toxicity of the drugs. In these type of patients, Child-Pugh score represents a poor prognostic factor to assess the metabolic capacity of the failing liver. * Metabolic performance of the liver depends on several factors: * Hepatic flow rate * Cytochrome P-450 enzimatic activity * Albumin affinity for the drug * Extrahepatic clearance for the drug In patients with hepatic failure, drugs that are only metabolized in the liver, accumulate in the plasma right after they are administered, and therefore it is needed to modify drug dosing in both, concentration and time intervals, to lower the risk of toxicity. It is also necessary to adjust the dosing for those drugs that are exclusively metabolized by the liver, and have low affinity for prioteins and high distribution volume, such as fluoroquinolones (Effects of MARS on Survival
In the meta-analysis published by Khuroo ''et al.''. which included 4 randomized trials an improvement in survival for the patients with liver failure treated with MARS, compared with SMT, was not observed. However, neither in the extracorporeal liver support systems review by the Cochrane (published in 2004), nor the meta-analysis by Kjaergard ''et al.''. was a significance difference in survival found for patients diagnosed with ALF treated with extracorporeal liver support systems. Nevertheless, these reviews included all kind of liver support systems and used a heterogeneous type of publication ( abstracts, clinical trials, cohort, etc.). There is literature showing favorable results in survival for patients diagnosed with ALF, and treated with MARS., In a randomized controlled trial, Salibà ''et al.''. studied the impact on survival of MARS therapy for patients with ALF, waiting on the liver transplant list. Forty-nine patients received SMT and 53 were treated with MARS. They observed that patients that received 3 or more MARS sessions showed a statistically significance increase in transplant-free survival compared with the others patients of the study. Notably, 75% of the patients underwent liver transplantation in the first 24 hours after inclusion in the waiting list, and besides the short exposure to MARS therapy, some patients showed a better survival trend compared to controls, when they were treated with MARS prior to the transplant. In a case-controlled study by Montejo ''et al.''. it was reported that MARS treatment do not decrease mortality directly; however, the treatment contributed to significantly improve survival in patients that were transplanted. In studies by Mitzner ''et al.''. and Heemann ''et al.''. they were able to show a significance statistical difference in 30-day survival for patients in the MARS group. However, El Banayosy ''et al.''. and Hassanein ''et al.''. noticed a non significant improvement in survival, probably because of the short number of patients included in the trials. In the majority of available MARS studies published with patients diagnosed with ALF, either transplanted or not, survival was greater in the MARS group with some variations according to the type of trial, ranging from 20-30%, and 60-80%. Data is summarized in Tables 8, 9 and 10.Safety Aspects
Safety, defined as presence of adverse events, is evaluated in few trials. Adverse events in patients receiving MARS therapy are similar to those in the controls with the exception of thrombocytopenia and hemorrhage that seems to occur more frequently with the MARS system. Heemann et al. reported two adverse events most probably MARS related: fever and sepsis, presumably originated at the catheter. In the study by Hassanein ''et al.'', two patients in the MARS group abandoned the study owing to hemodynamic instability, three patients required larger than average platelets transfusion and three more patients presented gastrointestinal bleeding. Laleman ''et al.''. detected one patient with thrombocytopenia in both the MARS and Prometheus treatment groups, and an additional patient with clotting of the dialysis circuit and hypotension, only in the Prometheus group. Kramer ''et al.''. (Biologic-DT) wrote about 3 cases with disseminated intravascular coagulation in the interventional group, two of them with fatal outcomes. Mitzner ''et al.''. described, among patients treated with MARS, a thrombocytopenia case and a second patient with chronic hepatitis B, who underwent TIPS placement on day 44 after randomization and died on day 105 of multiorgan failure, as a consequence of complications related to the TIPS procedure. Montejo ''et al.''. showed that MARS is an easy technique, without serious adverse events related to the procedure, and also easy to implement in ICU settings that are used to renal extracorporeal therapies. The MARS International Registry, with data from more than 500 patients (although sponsored by the manufacturer), shows that the adverse effects observed are similar to the control group. However, in these severely ill patients it is difficult to distinguish between complications of the disease itself and side effects attributable to the technique.Health Economics
Only three Studies addressing cost-effectivenenss of MARS therapy have been found. Hassanein et al. analysed costs of randomized patients with ACLF receiving MARS therapy or standard medical care. They used the study published in 2001 by Kim et al. describing the impact of complications in hospitalization costs in patients diagnosed with alcoholic liver failure. Cost of 11 patients treated with standard medical care (SMT) were compared to those that received MARS, in addition to SMT (12 patients). In the MARS group, there was less in-hospital mortality and complications related to the disease, with a remarkable reduction in cost which compensated the MARS related expenditure (Table 11). There were 5 survivors in the control group, with a cost per patient of $35.904, whereas in the MARS group, 11 patients out of 12 survived with a cost per patient of $32.036 which represents a $4000 savings per patient in favors of the MARS group. Hessel et al. published a 3-year follow-up of a cohort of 79 patients with ACLF, of whom 33 received MARS treatments and 46 received SMT. Survival was 67% for the MARS group and 63% for the controls, that was reduced to 58 and 35% respectively at one year follow-up, and then 52 and 17% at three years. Hospitalization costs for the MARS treated group were greater than that for the controls (€31,539 vs. €7,543) and similarly direct cost at 3-year follow-up (€8,493 vs. €5,194). Nevertheless, after adjusting mortality rate, the annual cost per patient was €12,092 for controls and €5,827 for MARS group; also in the latter, they found an incremental cost-effectiveness ratio of 31.448 € per life-year gained (LYG) and an incremental costs per QALY gained of 47171 €. Two years later, same authors published the results of 149 patients diagnosed with ACLF. There were 67 patients (44,9%) treated with MARS and 82 patients (55,1%) were allocated to receive SMT. Mean survival time was 692 days in the MARS group (33% at 3 years) and 453 days in the controls (15% at 3 years); the results were significant (p=0,022). Differences in average cost was €19,853 (95% IC: 13.308-25.429): 35.639 € for MARS patients and 15.804 € for the control group. Incremental cost per LYG was 29.985 € (95% IC: 9.441-321.761) and €43,040 (95% IC: 13.551-461.856) per quality-adjusted life years (QALY). Liver support systems, such as MARS, are very important to stabilize patients with acute or acute on chronic liver failure and avoid organ dysfunction, as well as a bridge-to-transplant. Although initial in-hospital costs are high, they are worth for the favorable outcome.MARS Therapy Indications
Acute on Chronic Liver Failure
Etiology: * Chronic viral hepatitis * Alcoholic liver disease * Autoimmune disease * Metabolic disease such as hemochromatosis * Idiopathic Cirrhosis Goals of MARS Therapy * Re-compensation of previous chronic state. * Prolong survival time and bridge to urgent or elective transplant * Pre-transplant optimization of the patient MARS Therapy Indication * Bilirubin > 15 mg/dl (255 μmol/L), not responding to standard medical care alter 3 days * Renal dysfunction or hepatorenal syndrome. * Hepatic encephalopathy ≥ II Treatment Schedule: * 3 to 5 eight-hour treatment sessions on consecutive days * Continuous treatment with hemodynamic instability (in any case, treatment kit must be replaced every 24 hours)Acute Liver failure
Etiology: * Viral infection * Poisoning (paracetamol overdose, mushrooms) * Multiorgan dysfunction (severe sepsis) * Vascular diseases (Budd Chiari syndrome) * Hypoxic hepatitis * Liver failure during pregnancy or Reye syndrome * Unknown etiology Goals of MARS Therapy * Native liver recovery. * Bridging to liver transplant * Pre-transplant optimization of the patient. MARS Therapy Indication * King's College or Clichy criteria for liver transplantation * Hepatic encephalopathy ≥ II * Increased intracraneal pressure * Acute hypoxic hepatitis with bilirubin > 8 mg/dl (100 μmol/L) * Renal dysfunction or hepatorenal syndrome * Progressive intrahepatic cholestasis * Fulminant Wilson disease * Acute liver dysfunction following paracetamol overdose Treatment Schedule: * 3 to 5 eight-hour treatment sessions in consecutives days * Hypoxic hepatitis. 3 eight-hour treatment sessions in consecutives days * Paracetamol overdose: 3 to 5 twenty four-hour treatment sessions * Mushroom poisoning: 3 to 5 twenty four-hour treatment sessions * Fulminant Wilson: minimum 5 twenty four-hour treatment sessions owing to copper saturation of the treatment kit * Drug overdose: 3 to 5 eight-hour treatment sessions in consecutives daysMARS in Graft Dysfucntion After Liver Transplant
Etiology: * Graft damage during preparation and transportation * Infection * Hepatotoxic drugs * Graft rejection * Technical complications (vascular, biliary) * Recurrence of primary disease Goals of MARS Therapy * Recovery and prevention of re-transplantation * • Prolong survival time and stabilize the patient to receive a re-transplant if the above goal is not achieved MARS Therapy Indication * Primary graft dysfunction * Hepatic encephalopathy ≥ II * Increased intracranial pressure * Renal dysfunction or hepatorenal syndrome. * Progressive intrahepatic cholestasis Treatment Schedule: * 3 to 5 eight-hour treatment sessions on consecutive days * Continuous treatment with hemodynamic instability (in any case, treatment kit must be replaced every 24 hours)MARS in liver Failure after Liver Surgery
Etiology: * Liver Resection in hepatocellular carcinoma * Transarterial Chemoembolization (TACE) * Partial resection in living donor transplantation * Other surgical interventions Goals of MARS Therapy * Recovery until hepatic regeneration MARS Therapy Indication * Hepatic encephalopathy ≥ II * Renal dysfunction or hepatorenal syndrome. * Progressive intrahepatic cholestasis Treatment Schedule: * 3 to 5 eight-hour treatment sessions on consecutive days * Continuous treatment with hemodynamic instability (in any case, treatment kit must be replaced every 24 hours)MARS for intractable pruritus in Cholestasis
Etiology: * Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) * Benign intrahepatic cholestasis (BIC) * Biliary Atresia Goals of MARS Therapy * Attenuate pruritus symptoms and improve patients’ quality of life MARS Therapy Indication * Pruritus not responding to SMT Treatment Schedule: * 3 to 5 eight-hour treatment sessions in consecutives days * Repeat treatment when symptoms reoccurMARS Therapy Contraindications
Same contraindications as with any other extracorporeal treatment may be applied to MARS therapy. * Unstable hemodynamics with mean arterial pressure (MAP)< 55 mmHg despite vasoconstrictors administration * Uncontrolled hemorrhage * Severe coagulopathy * Severe thrombocytopeniaTreatment Parameters
Blood Flow The trend is to use high flow rates, although it is determined by the technical specifications of the combined machine and catheters’ size Intermittent treatments: * Without renal dysfunction, it is recommended a blood and albumin flow rates ranging from 150 to 250 mL/min Continuous treatments: * With or without renal impairment it is recommended to use flow rates from 100 to 150 mL/min. Dyalisate Flow Rate Intermittent treatments: * Without renal impairment: 1800 a 3000 mL/hour * With renal impairment: 3000 a 6000 mL/hour Continuous treatments: * Recommended flow rate: 1000 to 2000 mL/hour. Replacement Flow Rate * According to medical criteria and same as in CVVHD Heparin Anticoagulation Similarly to CVVHD, it depends on previous patient's coagulation status. In many cases it will not be needed, unless the patient presents a PTT inferior to 160 seconds. In patients with normal values, a bolus of 5000 to 10000 IU of heparin could be administered at the commencement of the treatment, followed by a continuous perfusion, to keep PTT in ratios from 1,5 to 2,5 or 160 to 180 seconds. Monitoring A biochemical analysis is recommended (liver and kidney profile, ionic, glucose) together with a hemogram at the end of first session and before starting the following one. Coagulation analysis must be also performed before starting the session to adjusting heparin dose. In case that medication susceptible to be eliminated by MARS is being administered, it is also recommended to monitor their levels in blood End of the Session * Once the treatment is finalized, blood should be returned following the unit procedure, and both catheter's lumens heparinized * For the next session a new kit must be used * For continuous treatments, kit must be changed by a new one every 24 hours * Treatment must be stopped before schedule owing to the particular circumstances listed below: # MAP inferior to 40 mmHg at least for 10 minutes # Air embolism of the extracorporeal circuit # Transmembrane pressure (TMP) greater than 600 mmHg. # Blood leak detection in the albumin circuit # Disseminated intravascular coagulation (DIC) # Severe active hemorrhageFDA Clearance (US only)
Federal Drug Administration (FDA) cleared, in a document dated on May 27, 2005, MARS therapy for the treatment of drug overdose and poisoning. The only requirement is that the drug or poison must be susceptible to be dialysed and removed by activated charcoal or anionic exchange resins. More recently, on December 17, 2012, MARS therapy has been cleared by the FDA for the treatment of hepatic encephalopathy due to a decompensation of a chronic liver disease Clinical trials conducted with MARS treatment in HE patients having a decompensation of chronic liver disease demonstrated a transient effect from MARS treatments to significantly decrease their hepatic encephalopathy scores by at least 2 grades compared to standard medical therapy (SMT). The MARS is not indicated as a bridge to liver transplant. Safety and efficacy has not been demonstrated in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patientsLiverNet
ThSee also
*References
Further reading
* * * * {{Cite journal , vauthors=Mitzner S, Klammt S, Stange J, Nöldge-Schomburg GF, Schmidt R , date=April 2005 , title= xtracorporeal blood purification in severe liver failure with the albumin dialysis MARS – impact on relevant intensive care parameters, journal=Anasthesiol Intensivmed Notfallmed Schmerzther , language=German , volume=40 , issue=4 , pages=199–206 , doi=10.1055/s-2004-826116 , pmid=15832238 Liver Medical treatments Digestive system procedures Hepatology Medical equipment Membrane technology